98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874999 | PMC |
http://dx.doi.org/10.1097/HEP.0000000000000963 | DOI Listing |
Metabolism
October 2025
Division of Gastroenterology and Hepatology, School of Medicine, Stanford University Medical Center, Palo Alto, CA, United States; Department of Epidemiology and Population Health, Stanford University Medical Center, Palo Alto, CA, United States; Stanford Cancer Institute, Stanford University Medica
Pancreatology
May 2025
Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
NPJ Breast Cancer
May 2025
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.
Breast cancer (BC) is a leading cause of death among women, with approximately 30% HER2-positive (HER2+). Although HER2-targeted therapies have improved outcomes for patients with HER2+ metastatic breast cancer (mBC), clinical challenges and prognostic variability remain. Tumor-infiltrating lymphocytes (TILs) have emerged as prognostic and predictive biomarkers in various tumors, including BC, but their role in HER2+ mBC is poorly understood.
View Article and Find Full Text PDFEndoscopy
May 2025
Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, United States.
Epilepsia Open
June 2025
Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
Objective: Epilepsy is associated with low socioeconomic standing and increases the risk of sick leave. Longer periods resulting in benefit payments are captured by administrative data, but the disease also entails a risk of repeated short sick leave periods, which have so far not been studied or quantified. The aim of this study was to describe the frequency of short sick leave in persons with epilepsy (PWE) and the characteristics of these PWE.
View Article and Find Full Text PDF